InflaRx Receives Nasdaq Deficiency Notice for Minimum Bid Price

Biopharmaceutical company has 180 days to regain compliance with $1 per share requirement.

Mar. 13, 2026 at 9:19pm

Got story updates? Submit your updates here. ›

InflaRx N.V., a biopharmaceutical company focused on anti-inflammatory therapeutics, announced that it has received a notice from Nasdaq indicating the company's ordinary shares have closed below the minimum $1.00 per share requirement for continued listing on the exchange. InflaRx has been provided an initial period of 180 calendar days, or until September 7, 2026, to regain compliance.

Why it matters

Maintaining Nasdaq listing is critical for InflaRx to access public capital markets and continue funding its drug development programs. The company's share price has fallen below the $1 minimum, putting its Nasdaq listing at risk if compliance is not regained within the allotted time period.

The details

InflaRx received the notice on March 11, 2026 from Nasdaq's Listing Qualifications Department. The company has 180 calendar days, until September 7, 2026, to regain compliance with the $1 minimum bid price rule. If InflaRx fails to do so, it may consider transferring its shares to the Nasdaq Capital Market, which would provide an additional 180 days to meet the requirement.

  • InflaRx received the Nasdaq deficiency notice on March 11, 2026.
  • InflaRx has until September 7, 2026 to regain compliance with the $1 minimum bid price.

The players

InflaRx N.V.

A biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system.

Nasdaq

The Nasdaq Stock Market, where InflaRx's ordinary shares are listed.

Got photos? Submit your photos here. ›

What’s next

If InflaRx fails to regain compliance by September 7, 2026, it may consider transferring its shares to the Nasdaq Capital Market, which would provide an additional 180 days to meet the $1 minimum bid price requirement.

The takeaway

Maintaining Nasdaq listing is crucial for InflaRx to access public capital and continue funding its drug development pipeline. The company must act quickly to address the share price deficiency and avoid potential delisting, which could significantly impact its business.